ClinicalTrials.gg
CompletedNCT02678884Updated Oct 20, 2026

Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study

An interventional study of 18-F FDG in Head and Neck Squamous Cell Carcinoma, sponsored by University Health Network, Toronto. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 20, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto — 6 open to participants now, 8 under way, none of them phase 3. Squamous Cell Carcinoma of Head and Neck · University Health Network, Toronto.

Enrollment
11th of 17
19 · median 30
Started
2014
the only one that year
No phase
8 of 21
3 open now
Registered
4th of 21
by date

Among the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2014, is one of 8 with no phase, and was the 4th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Squamous Cell Carcinoma of Head and Neck by University Health Network, Toronto, or all of them as a file.
02

Study summary

The purpose of this study is to see how useful the information provided from Positron Emission Tomography (PET) scans can be in the actual planning and delivery of radiation treatment to patients who have head and neck cancers. Patients participating in this study, will have (in addition to their routine tests) a PET scan before and during their radiation treatment. Following the intervention, patients will be followed as per standard practice.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma

Keywords

  • Head and Neck Squamous Cell Carcinoma
  • Radiation therapy
  • Head and Neck Cancers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Non-nasopharynx head and neck mucosal squamous cell carcinoma
  • Radiologically evident gross disease
  • Radiotherapy alone for curative intent
  • Age equal to or more than 18 years old
  • To be eligible for the second study PET-CT scan: FDG avid tumour (or minimum SUV of 2.5) on the first study PET-CT scan

Exclusion criteria

Exclusion Criteria:

  • Nasopharynx cancer
  • H\&N SCC skin
  • Distant (already known or if found on baseline CT-thorax)
  • Prior within the last 5 years (exclude non-H\&N SCC, BCC skin)
  • Prior chemotherapy within the last 5 years or concurrent chemotherapy/EGFR inhibitors
  • Prior head and neck radiotherapy
  • Inability to lie supine for study duration
  • Pregnancy
  • Inability to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Enrollment
19 participants (actual)

Study arms

  • Experimental
    HNSCC Patients receiving RT

    Drug: 18-F FDG

Interventions

06

What researchers measure

Primary outcomes

  1. Measure rate constant of 18F-FDG uptake in tumour and normal tissue with dynamic PET scanning before radiotherapy.

    Time frame: ~ 2 years

Secondary outcomes

  1. Measure rate constant of 18F-FDG uptake in tumour and inflammatory tissue with dynamic PET scanning during radiotherapy .

    Time frame: ~ 2 years

07

Study locations

1 site
  • University Health Network, Princess Margaret Cancer Center
    Toronto, Ontario M5G 2M9, Canada
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Oct 2014, a primary completion of Jan 2025 and a completion of Jan 2025. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Nov 2028 → Jan 2025 and completion Nov 2028 → Jan 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2014
First posted
Feb 10, 2016
Start
Oct 2014
Primary completionActual
Jan 13, 2025was Nov 2028
CompletionActual
Jan 13, 2025was Nov 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 20, 2026
Primary completion
Nov 2028→Jan 13, 2025 (actual)
Oct 20, 2026
Study completion
Nov 2028→Jan 13, 2025 (actual)
Oct 20, 2026
Enrollment
20 (estimated)→19 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Completed
    Primary completion Nov 2028→Jan 13, 2025 (now actual)
    Study completion Nov 2028→Jan 13, 2025 (now actual)
    Enrollment 20 (estimated)→19 (actual)
    + 5 other changes: index terms, verification date, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02678884
Responsible party
Sponsor
First posted
Feb 10, 2016
Start date
Oct 2014
Primary completion
Jan 13, 2025
Completion
Jan 13, 2025
Last update
Oct 20, 2026

Study contacts

John J Kim, MD
principal investigator · The Princess Margaret Cancer Foundation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorodeoxyglucose F18

Start the discussion